Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ANDA Approvals May Be Hindered By New Elemental Impurities Requirements

Feb 11 2018

• By Derrick Gingery

FDA entrance sign 2016

Related Content

ANDA Complete Responses Spike In FY 2018, But Why?

Jan 20 2018

GDUFA II Reviews Start Strong With High First-Cycle Approval Rate

Dec 04 2017

Manufacturing Regulatory Updates In Brief: Elemental Impurities, Class 3 Biowaivers, FDA Salt Policy

Dec 28 2017

ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?

Jul 27 2015

Additional Topics

United States Generic Drugs FDA Regulation Manufacturing Quality BioPharmaceutical

More from Generics

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window